Sign in Subscribe
Cancer

Nanoparticle-Based Delivery Systems Show Promise in Enhancing Antitumor Immunity

Strategic Insights

— 1 min read

Researchers from Jamia Hamdard University have discovered that CD4 T-cells play a crucial role in cancer immunology, and novel drug delivery systems, particularly nanoparticle-based formulations, can enhance antitumor immune responses while minimizing systemic toxicity. The study aimed to explore the immunological significance of CD4 T-cells in cancer and their modulation using novel drug delivery systems. The researchers evaluated various nanoparticle platforms, including liposomes, polymeric nanoparticles, dendrimers, gold, silver, and mesoporous silica, for their ability to target CD4 T-cells.

Key Takeaways:

  • CD4 T-cells are pivotal in cancer immunology, functioning as both tumor-suppressing and tumor-promoting agents depending on their differentiation and cytokine profiles.
  • Novel drug delivery systems, particularly nanoparticle-based formulations, offer a promising approach to enhancing antitumor immune responses while minimizing systemic toxicity.
  • Liposomes and polymeric nanoparticles efficiently transport cytokines, antigens, as well as immunological modulators to CD4 T-cells, enhancing antitumor immunity.
  • MHC II-coated nanoparticles expanded antigen-specific CD4 T-cells, while mRNA nano vaccines activated CD4 and CD8 responses.
  • Future advancements should focus on overcoming biological barriers, improving targeting, and optimizing clinical translation.
  • The study highlights the potential of nanoparticle-based delivery systems in selectively modulating CD4 T-cell responses in cancer therapy.

Statistics:

  • 16:1643791 (Frontiers in Pharmacology) - the identification number of the research study.
  • 2025 - the year of publication of the research study.
  • 16 (Frontiers in Pharmacology) - the volume number of the journal where the research study was published.
  • 51 (Vaccine Weekly) - the page number where the news report was cited.
  • 34 (Avenue Du Tribunal Federal) - the house number of the address of the publisher, Frontiers Media Sa.

Sources:

  • "Nanoengineered-based delivery systems to modulate CD4+ T cell responses in cancer: emerging paradigms in cancer immunotherapy." Frontiers in Pharmacology, 2025;16:1643791.
  • Frontiers in Pharmacology can be contacted at: Frontiers Media Sa, Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland.
  • Phone number and email address for Anukrati Agnihotri, School of Pharmaceutical Education and Research (SPER), Jamia Hamdard University, New Delhi, India (information not provided).
  • Publisher contact information for the journal Frontiers in Pharmacology is: Frontiers Media Sa, Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland.

Read more